DE69230372T2 - Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität - Google Patents

Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität

Info

Publication number
DE69230372T2
DE69230372T2 DE69230372T DE69230372T DE69230372T2 DE 69230372 T2 DE69230372 T2 DE 69230372T2 DE 69230372 T DE69230372 T DE 69230372T DE 69230372 T DE69230372 T DE 69230372T DE 69230372 T2 DE69230372 T2 DE 69230372T2
Authority
DE
Germany
Prior art keywords
biological activity
preparations
polyoxypropylen
polyoxyethylen
copolymere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69230372T
Other languages
English (en)
Other versions
DE69230372D1 (de
Inventor
R Emanuele
Robert Hunter
Paula Culbreth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
CytRx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27100911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69230372(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CytRx Corp filed Critical CytRx Corp
Application granted granted Critical
Publication of DE69230372D1 publication Critical patent/DE69230372D1/de
Publication of DE69230372T2 publication Critical patent/DE69230372T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/08—Saturated oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2618—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen
    • C08G65/2621—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups
    • C08G65/2624—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups containing aliphatic amine groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying
DE69230372T 1991-03-19 1992-03-18 Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität Expired - Fee Related DE69230372T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67328991A 1991-03-19 1991-03-19
US84787492A 1992-03-13 1992-03-13
PCT/US1992/002254 WO1992016484A1 (en) 1991-03-19 1992-03-18 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

Publications (2)

Publication Number Publication Date
DE69230372D1 DE69230372D1 (de) 2000-01-05
DE69230372T2 true DE69230372T2 (de) 2000-06-15

Family

ID=27100911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69230372T Expired - Fee Related DE69230372T2 (de) 1991-03-19 1992-03-18 Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität

Country Status (19)

Country Link
US (7) US5523492A (de)
EP (1) EP0576612B1 (de)
JP (1) JP2647556B2 (de)
KR (1) KR100224539B1 (de)
CN (1) CN1069741A (de)
AT (1) ATE187154T1 (de)
AU (1) AU662146B2 (de)
CA (1) CA2106474C (de)
CZ (1) CZ194693A3 (de)
DE (1) DE69230372T2 (de)
DK (1) DK0576612T3 (de)
ES (1) ES2140408T3 (de)
GR (1) GR3032726T3 (de)
HU (1) HUT67762A (de)
IE (1) IE920860A1 (de)
IL (1) IL101305A (de)
NO (1) NO307890B1 (de)
SK (1) SK100893A3 (de)
WO (1) WO1992016484A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
ES2140408T3 (es) 1991-03-19 2000-03-01 Cytrx Corp Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
AU695125B2 (en) * 1993-02-02 1998-08-06 Xoma Corporation Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
ES2189808T3 (es) * 1993-10-15 2003-07-16 Cytrx Corp Composiciones de aporte terapeutico y metodos de uso de las mismas.
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
EP1181937A3 (de) 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
AU6358898A (en) * 1996-09-09 1998-04-17 Alexander V Kabanov Fluorinated copolymeric pharmaceutical adjuncts
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
AU1312800A (en) * 1998-10-09 2000-05-01 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
KR20020022691A (ko) * 1999-06-08 2002-03-27 와이즈먼 앤드루 아미노옥시기를 포함하는 원자가 플랫폼 분자
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US20070092526A1 (en) * 2000-06-23 2007-04-26 Evans Robert K Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
ATE503463T1 (de) * 2000-10-20 2011-04-15 Vical Inc Gen-abgabeformulierungen zur behandlung ischämischer zustände
US6492881B2 (en) * 2001-01-31 2002-12-10 Compaq Information Technologies Group, L.P. Single to differential logic level interface for computer systems
CA2445612C (en) * 2001-04-24 2011-10-25 Purdue Research Foundation Methods and compositions for treating mammalian nerve tissue injuries
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
CN100438861C (zh) * 2002-07-29 2008-12-03 变换药品公司 含水2,6-二异丙基苯酚药物组合物
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US7381422B2 (en) * 2002-12-23 2008-06-03 Vical Incorporated Method for producing sterile polynucleotide based medicaments
CA2508279A1 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
WO2004084703A2 (en) 2003-03-24 2004-10-07 Biosphere Medical, Inc. Temporary embolization using inverse thermosensitive polymers
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
EP1663261A2 (de) * 2003-09-05 2006-06-07 Mannarsamy Balasubramanian Gereinigte polyoxypropylen/polyoxyethylen-copolymere und herstellungsverfahren dafür
WO2005037062A2 (en) 2003-10-14 2005-04-28 Pluromed, Inc. Confinement of kidney-stone fragments during lithotripsy
WO2005046438A2 (en) 2003-11-06 2005-05-26 Pluromed, Inc. Internal clamp for surgical procedures
JP4521547B2 (ja) * 2004-04-15 2010-08-11 株式会社サンメディカル技術研究所 血液ポンプの流量推定装置
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
ES2380047T3 (es) * 2005-02-25 2012-05-08 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca
US20100092505A1 (en) 2005-04-05 2010-04-15 Elisabetta Bianchi Method for Shielding Functional Sites or Epitopes on Proteins
BRPI0611278A2 (pt) 2005-05-02 2010-08-31 Gen Hospital Corp tratamento de litìase sem litotripsia
WO2007008697A2 (en) * 2005-07-08 2007-01-18 University Of Chicago Compositions and methods for refolding of denatured proteins
WO2008018892A2 (en) * 2005-12-22 2008-02-14 Pluromed, Inc. Methods and kits for treating lacerations and puncture wounds using inverse thermosensitive polymers
CA2659909A1 (en) * 2006-08-01 2008-02-07 Phrixus Pharmaceuticals, Inc. Treatment for chronic progressive heart failure
JP5513115B2 (ja) 2006-09-11 2014-06-04 プルーロームド インコーポレイテッド 非外傷性閉塞バルーン及びスカート並びにその使用方法
EP2094169A4 (de) * 2006-12-11 2016-05-04 Pluromed Inc Hämostase bei durchbluteten organen
KR20160089544A (ko) * 2007-02-22 2016-07-27 플루로메드, 인코포레이티드 수술후 생물학적 유체 흐름을 제어하기 위한 역 감열 폴리머의 용도
MX2009010778A (es) * 2007-04-05 2010-01-29 Phrixus Pharmaceuticals Inc Composiciones y metodos para el tratamiento de insuficiencia cardiaca.
JP2010535772A (ja) * 2007-08-10 2010-11-25 シンスラックス インコーポレイテッド 慢性的微小血管障害を治療するためのポリマー療法
KR101383476B1 (ko) 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
EP2219546B1 (de) 2007-11-29 2017-02-01 Genzyme Corporation Endoskopische schleimhaut-resektionierung mit gereinigten inversen wärmeempfindlichen polymeren
JP5560201B2 (ja) * 2007-12-17 2014-07-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 骨格筋欠損症を治療および予防するための組成物および方法
JP5795961B2 (ja) * 2008-10-21 2015-10-14 ザ ジェネラル ホスピタル コーポレイション 細胞移植
DE102008043343A1 (de) * 2008-10-31 2010-05-06 Evonik Goldschmidt Gmbh Silikonpolyetherblock-Copolymere mit definierter Polydispersität im Polyoxyalkylenteil und deren Verwendung als Stabilisatoren zur Herstellung von Polyurethanschäumen
WO2010072769A1 (de) 2008-12-23 2010-07-01 Basf Se Verfahren zur herstellung von polyether-blockcopolymeren
WO2011049958A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
GB201008902D0 (en) 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
WO2012019103A2 (en) 2010-08-06 2012-02-09 The General Hospital Corporation D/B/A System and apparatus for cell treatment
WO2012068079A1 (en) * 2010-11-15 2012-05-24 Adventrx Pharmaceuticals, Inc. Methods for enhancing oxygenation of jeopardized tissue
MX362554B (es) 2011-03-18 2019-01-24 Baxter Healthcare Sa Soluciones de dialisis peritoneal que comprenden polimeros de glucosa.
FR2977495B1 (fr) * 2011-07-07 2014-03-07 Sanofi Sa Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation
US9662345B2 (en) 2013-06-14 2017-05-30 Professional Compounding Centers Of America Antibiotic composition for inhalation and irrigation
WO2015058013A1 (en) 2013-10-16 2015-04-23 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
JP6202471B2 (ja) 2013-10-31 2017-09-27 日油株式会社 医用ポリオキシプロピレン重合体の製造方法および医用ポリオキシプロピレン／ポリオキシエチレンブロック共重合体の製造方法
US20160000823A1 (en) * 2014-07-07 2016-01-07 Mast Therapeutics, Inc. Methods and compositions for improving hemostasis
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
TWI688392B (zh) * 2014-07-07 2020-03-21 美商救生筏生物科技公司 無長循環材料之泊洛沙姆組成物以及其製造方法和用途
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
CN108473673B (zh) * 2015-12-22 2020-12-01 巴斯夫欧洲公司 一种纯化聚醚嵌段共聚物的方法
CN110268001A (zh) * 2017-02-09 2019-09-20 巴斯夫欧洲公司 纯化聚醚嵌段共聚物的方法
WO2019125783A1 (en) * 2017-12-21 2019-06-27 Sigma-Aldrich Co. Llc Poloxamer compositions and methods of making and using same
MX2019012352A (es) 2018-10-15 2020-08-20 Avent Inc Composiciones, sistemas, kits y metodos para ablacion neural.

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2979528A (en) * 1953-10-19 1961-04-11 Wyandotte Chemicals Corp Nitrogen-containing polyoxyalkylene detergent compositions
US2674619A (en) * 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
US3022335A (en) * 1955-03-30 1962-02-20 Wyandotte Chemicals Corp Surface active polyoxyalkylene compounds having a plurality of heteric polyoxypropylene-polyoxyethylene chains
US2854378A (en) * 1955-12-08 1958-09-30 Bristol Lab Inc Tetracycline suppository
US3036118A (en) * 1957-09-11 1962-05-22 Wyandotte Chemicals Corp Mixtures of novel conjugated polyoxyethylene-polyoxypropylene compounds
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US3228834A (en) * 1962-06-08 1966-01-11 Hoffmann La Roche Pharmaceutical diluent compositions
US3140232A (en) * 1962-12-19 1964-07-07 Pfizer & Co C Color stabilization of tetracycline compositions with polypropylene glycols
US3391196A (en) * 1965-08-16 1968-07-02 Wyandotte Chemicals Corp High equivalent weight hydroxy-terminated ethylene oxide-butylene oxide polyether polyols
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3450502A (en) * 1967-09-25 1969-06-17 Wyandotte Chemicals Corp Method of operating heart-lung apparatus
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3867533A (en) * 1968-12-20 1975-02-18 Basf Wyandotte Corp Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US3577522A (en) * 1969-10-10 1971-05-04 Wyandotte Chemicals Corp Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes
US3590125A (en) * 1969-10-10 1971-06-29 Wyandotte Chemicals Corp Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
CA959759A (en) * 1970-01-15 1974-12-24 John J. Miskel Method for absorption of drugs
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3997458A (en) * 1974-04-12 1976-12-14 Deknatel, Incorporated Method of cleansing contaminated wounds and surgical scrub solutions for same
US4104455A (en) * 1975-03-25 1978-08-01 Toyo Soda Manufacturing Co., Ltd. Polymerization of monomer
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4195167A (en) * 1976-05-28 1980-03-25 Union Carbide Corporation Gradient polymers of two or more cyclic, organic, ring-opening, addition polymerizable monomers and methods for making same
JPS545094A (en) 1977-06-09 1979-01-16 Tokyo Tanabe Co Production of pharmaceutical urokinase from contamination free human urine
DE2732929A1 (de) * 1977-07-21 1979-02-01 Bayer Ag Polyaether, verfahren zu ihrer herstellung sowie ihre verwendung als lipidabsorptionshemmer
DE2961374D1 (en) * 1978-01-27 1982-01-28 Bp Chem Int Ltd A method for increasing the selectivity to acetic acid in the production of a mixture of c1 to c3 monocarboxylic acids by oxidation of paraffinic hydrocarbons
DE2808865A1 (de) * 1978-03-02 1979-09-13 Hoechst Ag Mikrobiozide mittel auf der basis von alkyl-di-guanidinium-salzen
US4275244A (en) * 1978-05-11 1981-06-23 Basf Wyandotte Corporation Linear polyalkylene ether glycols of high molecular weight
JPS5533194A (en) 1978-08-07 1980-03-08 Scholz D Thomas Stringgfastener device including tremolant
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
DE2850058A1 (de) * 1978-11-18 1980-05-29 Bayer Ag Polyaether-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2454409A1 (fr) * 1979-04-18 1980-11-14 Sovam Vehicule tracteur notamment pour avions gros porteurs
US4409209A (en) * 1979-10-12 1983-10-11 Ciba-Geigy Corporation Novel phosphorylmuramyl peptides and processes for the manufacture thereof
FI803077A (fi) * 1979-10-12 1981-04-13 Ciba Geigy Ag Foerfarande foer framstaellning av myramylpeptider
US4575484A (en) * 1980-05-05 1986-03-11 Montefiore Medical Center, Inc. Binding assay for the detection of mycobacteria
US4410660A (en) * 1980-05-05 1983-10-18 Montefiore Medical Center Binding assay for the detection of mycobacteria
US4489158A (en) * 1980-05-05 1984-12-18 Montefiore Hospital And Medical Center, Inc. Binding assay for the detection of mycobacteria
JPS578223A (en) * 1980-06-19 1982-01-16 Mitsui Petrochem Ind Ltd Production of alkylene oxide block copolymer
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4376118A (en) * 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
GR78246B (de) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4395393A (en) * 1981-08-10 1983-07-26 Basf Wyandotte Corporation Artificial blood emulsifiers
US4407790A (en) * 1981-09-25 1983-10-04 Economics Laboratory, Inc. Method of controlling bloat using nonionic surfactants
EP0098110B1 (de) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Zusammensetzung mit längerer Wirkung
DE3234084A1 (de) * 1982-09-14 1984-03-15 B. Braun Melsungen Ag, 3508 Melsungen Pharmazeutische zubereitungen zur behandlung von unerwuenschten verwachsungen sowie deren verwendung
SU1183112A1 (ru) * 1983-08-04 1985-10-07 Научно-Исследовательский Институт Экспериментальной И Клинической Терапии Министерства Здравоохранения Гсср Способ лечени острой ишемии миокарда
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4600652A (en) * 1985-04-01 1986-07-15 Warner-Lambert Company Permanently bonded antithrombogenic polyurethane surface
US5183687A (en) * 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
WO1987006836A1 (en) * 1986-05-15 1987-11-19 Emory University Fibrinolytic composition
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
JP2527942B2 (ja) * 1986-09-18 1996-08-28 ティーディーケイ株式会社 磁気記録媒体
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4764567A (en) * 1986-11-20 1988-08-16 Basf Corporation Process for the preparation of polyoxyalkylene block polyethers having enhanced properties
DE3875871T2 (de) * 1987-02-20 1993-04-01 Univ Emory Antiinfektioese verbindungen und verfahren zur verwendung.
US5811088A (en) 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
JPH07109520B2 (ja) 1987-02-24 1995-11-22 株式会社リコー 電子写真用感光体
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE4014923A1 (de) * 1990-05-10 1991-11-14 Basf Ag Verfahren zur herstellung von urethan- oder urethan- und isocyanuratgruppen enthaltenden hartschaumstoffen nach dem polyisocyanat-polyadditionsverfahren und die hierfuer geeigneten polyoxyalkylen-polyole
ES2140408T3 (es) * 1991-03-19 2000-03-01 Cytrx Corp Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
US5294365A (en) * 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants
US5371253A (en) * 1993-12-14 1994-12-06 Arco Chemical Technology, L.P. Process for producing esterified alkoxylated monoglycerides and diglycerides

Also Published As

Publication number Publication date
EP0576612A1 (de) 1994-01-05
CN1069741A (zh) 1993-03-10
HUT67762A (en) 1995-04-28
IL101305A0 (en) 1992-11-15
US20020183398A1 (en) 2002-12-05
ES2140408T3 (es) 2000-03-01
SK100893A3 (en) 1994-04-06
AU662146B2 (en) 1995-08-24
CA2106474A1 (en) 1992-09-20
NO307890B1 (no) 2000-06-13
NO933337L (no) 1993-11-17
AU1773092A (en) 1992-10-21
NO933337D0 (no) 1993-09-17
KR100224539B1 (ko) 1999-10-15
US6359014B1 (en) 2002-03-19
USRE37285E1 (en) 2001-07-17
IE920860A1 (en) 1992-09-23
IL101305A (en) 1995-11-27
ATE187154T1 (de) 1999-12-15
EP0576612A4 (de) 1994-11-09
WO1992016484A1 (en) 1992-10-01
US5523492A (en) 1996-06-04
EP0576612B1 (de) 1999-12-01
GR3032726T3 (en) 2000-06-30
JP2647556B2 (ja) 1997-08-27
CZ194693A3 (en) 1994-03-16
US5990241A (en) 1999-11-23
US6747064B2 (en) 2004-06-08
JPH06506258A (ja) 1994-07-14
DK0576612T3 (da) 2000-05-22
HU9302628D0 (en) 1993-12-28
CA2106474C (en) 2004-02-10
US5691387A (en) 1997-11-25
DE69230372D1 (de) 2000-01-05
USRE36665E (en) 2000-04-18

Similar Documents

Publication Publication Date Title
DE69230372D1 (de) Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
ES2082003T3 (es) Deshidrodidemnina b.
DK0611522T3 (da) Synergistiske mikrobicide sammensætninger
PL308122A1 (en) Viral vectors and their application in genic therapy
DK480284D0 (da) Sporstofmaerkede konjugater af metallothionein og maalsoegende, biologisk aktive molekyler
DE69331762T2 (de) "heat shock"-proteine und behandlung von tumoren
TR28384A (tr) Flüoroalifatik -ve karboksil- iceren terminal gruplarina sahip polisilokzanlar, bunlarin hazirlanmasi, ve lifli malzemelerin muamelesinde kullanimlari.
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE3884453D1 (de) Homogene additionscopolymere von ethylen und cycloolefinmonomeren und deren herstellung.
ATE208208T1 (de) Halogenid-enthaltende insulinzubereitungen
SE9101815L (sv) Behandling av sjukdom foerbunden med hiv-infektioner
ITMI912456A0 (it) Ossa(tia)diazol- e triazol-oni(tioni)ad attivita' acarcida ed insetticida
RS49520B (sr) Antimikrobno aktivne smeše
MY107501A (en) Continuously magnetizing magnet.
DE69328437D1 (de) Interleukine-6 Mutante mit verbesserter biologischer Aktivität im vergleich zu wildtyp IL-6
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
DE69016693D1 (de) Züchtung von transformierten Mikroorganismen.
GEP20012489B (en) Use of Natural Human α-Interferon
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
ES2077614T3 (es) Bacillus thuringiensis, variedad donegani, y preparacion o toxina obtenida de esta, dotado de actividad insecticida frente a cleopteros.
RU93056161A (ru) Блок-сополимер полиоксипропилена и полиоксиэтилена, поверхностно-активный сополимер, способ получения нетоксичного поверхностно-активного сополимера, лекарственное средство
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
SU1536770A1 (ru) Хлорид бензилгексаметилентетраммония, обладающий бактерицидной активностью в отношении сульфатвосстанавливающих бактерий и культур pseudomonas
Cyr Self-disclosure by marital therapists and consequent spouse responses.
KR930022878U (ko) 가구의 고저수평 조절구

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee